Location History:
- New Castle, DE (US) (1994 - 1999)
- Wilmington, DE (US) (1999)
Company Filing History:
2 out of 106 
1 out of 206 Years Active: 1994-1999
Title: The Innovations of Robert Frank Kaltenbach, III
Introduction
Robert Frank Kaltenbach, III is an accomplished inventor based in New Castle, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit HIV protease. With a total of 3 patents to his name, Kaltenbach's work has had a meaningful impact on medical research and treatment options.
Latest Patents
Kaltenbach's latest patents include innovative compounds such as 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas, which are useful as inhibitors of HIV protease. This invention relates to compounds that can be utilized in pharmaceutical compositions and diagnostic kits for treating viral infections. Another notable patent involves a process for the preparation of diamine intermediates, which serve as essential components in the synthesis of HIV protease inhibitors, including cyclic ureas.
Career Highlights
Throughout his career, Kaltenbach has worked with prominent companies in the pharmaceutical industry, including DuPont Pharmaceuticals Company and the DuPont Merck Pharmaceutical Company. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical science.
Collaborations
Kaltenbach has collaborated with notable colleagues such as James David Rodgers and Jung-Hui Sun. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmaceutical research.
Conclusion
Robert Frank Kaltenbach, III is a distinguished inventor whose work in HIV protease inhibitors has made a significant impact on the pharmaceutical industry. His innovative patents and collaborations highlight his dedication to advancing medical research and improving treatment options for viral infections.